Abstract
Lasmiditan (REYVOW (TM); Eli Lilly and Company) is an orally available serotonin (5-HT)(1F) receptor agonist. In October 2019, the US FDA approved las......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
